A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs)

Journal of Biomolecular Screening

Volumn 20, Issue 6, 2015, Pages 748-759

  Callis, Rowena ^a   Rabow, Alfred ^a   Tonge, Michael ^a   Bradbury, Robert ^a   Challinor, Mairi ^a   Roberts, Karen ^a   Jones, Karen ^a   Walker, Graeme ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

cell based assays; estrogen receptor; screening cascade; SERD

Indexed keywords

4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; AFIMOXIFENE; ESTROGEN RECEPTOR; FULVESTRANT; GW 7604; HISTONE DEACETYLASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SS 5020; TAMOXIFEN; UNCLASSIFIED DRUG; VORINOSTAT; ESTROGEN RECEPTOR ALPHA; MOLECULAR LIBRARY; PROGESTERONE RECEPTOR; PROTEIN BINDING;

ARTICLE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DOSE RESPONSE; DOWN REGULATION; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MOLECULAR LIBRARY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ESTROGEN RECEPTOR ALPHA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN BINDING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84931301519     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115580298     Document Type: Article

References (34)

1. Green S., Walter P., Kumar V., et al. Human Oestrogen Receptor cDNA: Sequence, Expression and Homology to v-erb-A. Nature. 1986 ; 320: 134-139
2. Greene G. L., Gilna P., Waterfield M., et al. Sequence and Expression of Human Estrogen Receptor Complementary DNA. Science. 1986 ; 231: 1150-1154
3. Ariazi E. A., Ariazi J. L., Cordera F., et al. Estrogen Receptors as Therapeutic Targets in Breast Cancer. Curr. Top. Med. Chem. 2006 ; 6: 181-202
4. Jordan V. C.. Tamoxifen: A Most Unlikely Pioneering Medicine. Nat. Rev. Drug Discov. 2003 ; 2: 205-213
5. Morris C., Wakeling A.. Fulvestrant ('Faslodex'): A New Treatment Option for Patients Progressing on Prior Endocrine Therapy. Endocr. Relat. Cancer. 2002 ; 9: 267-276
6. Scott S. M., Brown M., Come S. E.. Emerging Data on the Efficacy and Safety of Fulvestrant, a Unique Antiestrogen Therapy for Advanced Breast Cancer. Expert Opin. Drug Saf. 2011 ; 10: 819-826
7. Osborne C. K., Schiff R.. Mechanisms of Endocrine Resistance in Breast Cancer. Ann. Rev. Med. 2011 ; 62: 233-247
8. Damodaran S., Majumdr S., Ramaswamy B.. Endocrine Resistance Mechanisms and Therapeutic Targets. Clin. Investig. 2013 ; 3: 681
9. Jordan V. C.. Biochemical Pharmacology of Antiestrogen Action. Pharmacol. Rev. 1984 ; 36: 245-276
10. Wijayaratne A. L., McDonnell D. P.. The Human Estrogen Receptor-Alpha Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor Modulators. J. Biol. Chem. 2001 ; 276: 35684-35692
11. Osborne C. K., Wakeling A., Nicholson R. I.. Fulvestrant: An Oestrogen Receptor Antagonist with a Novel Mechanism of Action. Br. J. Cancer. 2004 ; 90 (Suppl. 1). S2 - S6
12. Robertson J. F., Harrison M.. Fulvestrant: Pharmacokinetics and Pharmacology. Br. J. Cancer. 2004 ; 90 (Suppl. 1). S7 - S10
13. Howell A., Sapunar F.. Fulvestrant Revisited: Efficacy and Safety of the 500-Mg Dose. Clin. Breast Cancer. 2011 ; 11: 204-210
14. Robertson J. F.. Fulvestrant (Faslodex): How to Make a Good Drug Better. Oncologist. 2007 ; 12: 774-784
15. Wardell S. E., Marks J. R., McDonnell D. P.. The Turnover of Estrogen Receptor Alpha by the Selective Estrogen Receptor Degrader (SERD) Fulvestrant Is a Saturable Process That Is Not Required for Antagonist Efficacy. Biochem. Pharmacol. 2011 ; 82: 122-130
16. Willson T. M., Henke B. R., Momtahen T. M., et al. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats. J. Med. Chem. 1994 ; 37: 1550-1552
17. Suzuki N., Liu X., Laxmi Y. R., et al. Anti-Breast Cancer Potential of SS5020, a Novel Benzopyran Antiestrogen. Int. J. Cancer. 2011 ; 128: 974-982
18. Kieser K. J., Kim D. W., Carlson K. E., et al. Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs). J. Med. Chem. 2010 ; 53: 3320-3329
19. Horwitz K. B., McGuire W. L.. Estrogen Control of Progesterone Receptor in Human Breast Cancer: Correlation with Nuclear Processing of Estrogen Receptor. J. Biol. Chem. 1978 ; 253: 2223-2228
20. Seo H. S., Larsimont D., Querton G., et al. Estrogenic and Anti-Estrogenic Regulation of Estrogen Receptor in MCF-7 Breast-Cancer Cells: Comparison of Immunocytochemical Data with Biochemical Measurements. Int. J. Cancer. 1998 ; 78: 760-765
21. Fan M., Park A., Nephew K. P.. CHIP (Carboxyl Terminus of Hsc70-Interacting Protein) Promotes Basal and Geldanamycin-Induced Degradation of Estrogen Receptor-Alpha. Mol. Endocrinol. 2005 ; 19: 2901-2914
22. Marsaud V., Gougelet A., Maillard S., et al. Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor Alpha (ERalpha), Differentially Affect ERalpha Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells. Mol. Endocrinol. 2003 ; 17: 2013-2027
23. Valley C. C., Solodin N. M., Powers G. L., et al. Temporal Variation in Estrogen Receptor-Alpha Protein Turnover in the Presence of Estrogen. J. Mol. Endocrinol. 2008 ; 40: 23-34
24. Margueron R., Duong V., Castet A., et al. Histone Deacetylase Inhibition and Estrogen Signalling in Human Breast Cancer Cells. Biochem. Pharmacol. 2004 ; 68: 1239-1246
25. Feng Q., Zhang Z., Shea M. J., et al. An Epigenomic Approach to Therapy for Tamoxifen-Resistant Breast Cancer. Cell Res. 2014 ; 24: 809-819
26. Shapiro A. B., Walkup G. K., Keating T. A.. Correction for Interference by Test Samples in High-Throughput Assays. J. Biomol. Screen. 2009 ; 14: 1008-1016
27. Filippakopoulos P., Qi J., Picaud S., et al. Selective Inhibition of BET Bromodomains. Nature. 2010 ; 468: 1067-1073
28. Zhang J. H., Chung T. D., Oldenburg K. R.. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999 ; 4: 67-73
29. Leeson P. D., Springthorpe B.. The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry. Nature Reviews Drug Disc. 2007 ; 6: 881-890
30. Levenson A. S., Jordan V. C.. MCF-7: The First Hormone-Responsive Breast Cancer Cell Line. Cancer Res. 1997 ; 57: 3071-3078
31. Wittmann B. M., Sherk A., McDonnell D. P.. Definition of Functionally Important Mechanistic Differences among Selective Estrogen Receptor Down-Regulators. Cancer Res. 2007 ; 67: 9549-9560
32. Kawai H., Li H., Avraham S., et al. Overexpression of Histone Deacetylase HDAC1 Modulates Breast Cancer Progression by Negative Regulation of Estrogen Receptor Alpha. Int. J. Cancer. 2003 ; 107: 353-358
33. Horwitz K. B., Koseki Y., McGuire W. L.. Estrogen Control of Progesterone Receptor in Human Breast Cancer: Role of Estradiol and Antiestrogen. Endocrinology. 1978 ; 103: 1742-1751
34. Horwitz K. B., McGuire W. L.. Estrogen Control of Progesterone Receptor Induction in Human Breast Cancer: Role of Nuclear Estrogen Receptor. Adv. Exp. Med. Biol. 1979 ; 117: 95-110